<![CDATA[Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma]]>

Summary

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, discuss the immunologic and mechanistic synergy between CELMoDs and standard myeloma backbone therapies including proteasome inhibitors and CD38 antibodies. This is an educational discussion piece with no new clinical data or trial results.